Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy

Clinical Epidemiology

Volumn 7, Issue , 2015, Pages 139-147

  Bro, Søren Pauli ^a   Kjaersgaard, Maiken Ina Siegismund ^b   Parner, Erik Thorlund ^b   Sørensen, Merete Juul ^c   Olsen, Jørn ^d   Bech, Bodil Hammer ^d   Pedersen, Lars Henning ^d,e   Christensen, Jakob ^c,f   Vestergaard, Mogens ^a  

^a Research Unit for General Practice   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d Department of Obstetrics and Gynaecology   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

^f Department of Clinical Pharmacology ^*  (Denmark)

Author keywords

ADHD; Atomoxetine; Attention defcit hyperactivity disorder; Methylphenidate; Pregnancy outcomes

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE;

ABORTION; ADULT; ADVERSE OUTCOME; APGAR SCORE; ARTICLE; ATTENTION DEFICIT DISORDER; COHORT ANALYSIS; CONGENITAL DISORDER; CONTROLLED STUDY; DENMARK; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; EMBRYO DEATH; FEMALE; HUMAN; INDUCED ABORTION; MAJOR CLINICAL STUDY; NEWBORN DEATH; POPULATION RESEARCH; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL EXPOSURE; RISK FACTOR; SPONTANEOUS ABORTION; STILLBIRTH;

EID: 84930007015     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S72906     Document Type: Article

References (25)

1. Chai G, Governale L, McMahon AW, Trinidad J P, Staffa J, Murphy D. Trends of outpatient prescription drug utilization in US children, 2002–2010. Pediatrics. 2012;130(1):23–31.
2. Pottegård A, Bjerregaard BK, Glintborg D, Kortegaard LS, Hallas J, Moreno SI. The use of medication against attention defcit hyperactivity disorder in Denmark: a drug use study from a patient perspective. Eur J Clin Pharmacol. 2013;69(3):589–598.
3. Sclar DA, Robinson LM, Bowen KA, Schmidt JM, Castillo LV, Organov AM. Attention-deficit/hyperactivity disorder among children and adolescents in the United States: trend in diagnosis and use of phar-macotherapy by gender. Clin Pediatr (Phila). 2012;51(6):584–589.
4. Robison LM, Skaer TL, Sclar DA, Gailin RS. Is attention deficit hyper-activity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants. CNS Drugs. 2002;16(2):129–137.
5. Winterstein AG, Gerhard T, Shuster J, et al. Utilization of pharmaco-logic treatment in youths with attention defcit/hyperactivity disorder in Medicaid database. Ann Pharmacother. 2008;42(1):24–31.
6. Hechtman L. Predictors of long-term outcome in children with attention-defcit hyperactivity disorder. Pediatr Clin North Am. 1999;46(5): 1039–1052.
7. Hinshaw S P, Owens EB, Zalecki C, et al. Prospective follow-up of girls with attention-defcit/hyperactivity disorder into early adulthood: continuing impairment includes elevated risk for suicide attempts and self-injury. J Consult Clin Psychol. 2012;80(6):1041–1051.
8. McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC. The epidemiology of pharmacologically treated attention defcit hyper-activity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr. 2012;12:78.
9. Haervig K, Mortensen L, Hansen A, Strandberg-Larsen K. Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. Pharmacoepidemoiol Drug Saf. 2014;23(5):526–533.
10. Teo SK, Stirling DI, Thomas SD, Hoberman AM, Christian MS, Khetani VD. The perinatal and postnatal toxicity of D-methylpheni-date and D,L-methylphenidate in rats. Reprod Toxicol. 2002;16(4): 353–366.
11. Teo SK, Stirling DI, Thomas SD, Hoberman AM, Christian MS, Khetani VD. D-methylphenidate and D,L-methylphenidate are not developmental toxicants in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol. 2003;68(2):162–171.
12. Beckman DA, Schneider M, Youreneff M, Tse FLS. Developmental toxicity assessment of d,l-methylphenidate and d-methylphenidate in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol. 2008;83(5): 489–501.
13. Smithells RW. Thalidomide and malformations in Liverpool. Lancet. 1962;1(7242):1270–1273.
14. Kopelman AE, McCullar F W, Heggeness L. Limb malformations following maternal use of haloperidol. JAMA. 1975;231(1):62–64.
15. Heinonen O P, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy: Maternal Drug Exposure and Congenital Malformations. Littleton (MA): Publishing Sciences Group; 1977.
16. Debooy VD, Seisha MM, Tenenbein M, Casiro OG. Intravenous penta-zocine and methylphenidate abuse during pregnancy. Am J Dis Child. 1993;147(10):1062–1065.
17. Dideriksen D, Pottegård A, Hallas J, Aagaard L, Damkier P. First trimester in utero exposure to methylphenidate. Basic Clin Pharmacol Toxicol. 2013;112(2):73–76.
18. Pottegård A, Hallas J, Andersen JT, et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry. 2014;75(1):e88–e93.
19. Efron B, Tibshirani RJ. Bootstrap methods for standard errors, con-fdence intervals and other measures of statistical accuracy. Stat Sci. 1986;1(1):54–75.
20. pro.medicin.dk [homepage on the internet]. Modafinil “Mylan”. Copenhagen: Dansk Lægemiddel Information; 2014 [updated January 16, 2014]. Available from: http://pro.medicin.dk/Medicin/ Praeparater/6716. Accessed October 7, 2014.
21. pro.medicin.dk [homepage on the internet]. Modiodal: modafnil. Copenhagen: Dansk Lægemiddel Information; 2014 [updated May 21, 2014]. Available from: http://pro.medicin.dk/Medicin/Praeparater/2520. Accessed October 7, 2014.
22. Casey BM, McIntire DD, Leveno KJ. The continuing value of the Apgar score for the assessment of newborn infants. New Engl J Med. 2001;344(7):467–471.
23. Sun Y, Vestergaard M, Pedersen C, Christensen J, Olsen J. Apgar scores and long-term risk of epilepsy. Epidemiology. 2006;17(3):296–301.
24. Olesen C, Søndergaard C, Thrane N, Nilensen GL, Jong-van den Berg L, Olsen J. Do pregnant women report use of dispensed medications? Epidemiology. 2001;12(5):497–501.
25. Kristensen J, Langhoff-Roos J, Skovgaard LT, Kristensen FB. Validation of the Danish Birth Registration. J Clin Epidemiol. 1996;49(8):893–897.